上海云晟研新生物科技

Shanghai Yunsheng Yanxin Biotechnology is a China-based biopharmaceutical company specializing in the discovery and development of innovative small molecule therapeutics for oncology. Founded in 2021 and headquartered in Shanghai's Zhangjiang Hi-Tech Park, the company focuses on targeting DNA damage response (DDR) pathways and synthetic lethality mechanisms. Its lead research program, YS-001, is a selective inhibitor of Ubiquitin-specific protease 1 (USP1) aimed at treating various solid tumors with specific genetic vulnerabilities. Backed by prominent investors like Sequoia China and Matrix Partners China, Yunsheng Yanxin leverages a deep understanding of cancer biology to address significant unmet medical needs in the global oncology market.